Drug intelligence / Profile preview

SHR-4712

Development stage: Phase 1
Lead developer: Hengrui Pharmaceutical

Overview

SHR-4712 is an investigational biological product currently in Phase 1 clinical development for the treatment of advanced malignant solid neoplasms. It is classified as a type I therapeutic biologic and is independently developed by Guangdong Hengrui Pharmaceutical. While its precise mechanism of action and molecular target have not been disclosed, SHR-4712 is being evaluated in first-in-human studies to assess its safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and anti-tumor activity in patients with advanced solid tumors[1][3][5][10].

Beyond the preview

Go deeper on SHR-4712.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHR-4712.

Explore the full profile